IP Library Granted Patent US 8,420,133
Granted Patent B2
US 8,420,133 · App. 13/588,877 · Granted Apr 16, 2013

Modified pectins, compositions and methods related thereto

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,420,133
App. No.
13/588,877
Granted
Apr 16, 2013
Kind
B2
Abstract

The present invention provides compositions of modified pectin and methods for preparing and using them.

Claims (22)

1. A composition comprising a colloidal solution of a purified modified pectin or a deesterified, partially depolymerized and purified modified pectin, wherein the colloidal solution comprises colloidal particles less than 1 micron in diameter that consist essentially of a purified modified pectin or a deesterified, partially depolymerized and purified modified pectin having an average molecular weight in the range of 70 to −175 kD.

2. The composition of claim 1 , wherein the average molecular weight of the modified pectin or deesterified and partially depolymerized modified pectin is from 80-150 kD.

3. The composition of claim 2 , wherein the average molecular weight of the modified pectin or deesterified and partially depolymerized modified pectin is from 80-100 kD.

4. The composition of claim 1 , wherein the average molecular weight of the modified pectin or deesterified and partially depolymerized modified pectin is from 70-150 kD.

5. The composition of claim 1 , wherein the composition is substantially free of modified pectins having molecular weights below 25 kD.

6. The composition of claim 1 , wherein the composition is an aqueous solution.

7. The composition of claim 6 , wherein the solution contains at least 0.5% by weight of the modified pectin or deesterified and partially depolymerized modified pectin.

8. The composition of claim 7 , wherein the solution contains at least 5% by weight of the modified pectin or deesterified and partially depolymerized modified pectin.

9. The composition of claim 1 , wherein the modified pectin or deesterified, partially depolymerized modified pectin is prepared by passing an aqueous solution of modified or unmodified pectin through a tangential flow filter.

10. The composition of claim 9 , wherein the aqueous solution of modified or unmodified pectin is prepared by sequentially subjecting an aqueous pectin solution to alkaline conditions and acidic conditions in either order.

11. The composition of claim 1 , wherein the colloidal particles are less than 0.20 μm in diameter.

12. The composition of claim 1 , wherein the composition comprises a purified modified pectin.

13. The composition of claim 1 , wherein the composition comprises a purified deesterified and partially depolymerized modified pectin.

14. The composition of claim 1 , wherein the modified pectin or deesterified and partially depolymerized modified pectin inhibits cancer proliferation with an IC 50 less than 200 μg/mL.

15. The composition of claim 14 , wherein the modified pectin or deesterified and partially depolymerized modified pectin inhibits cancer proliferation with an IC 50 in the range of 25-75 μg/mL.

16. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the composition of claim 1 .

17. A dosage form comprising a composition of claim 1 , wherein the dosage form is selected from dosage forms suitable for oral administration, topical administration and inhalation.

18. The dosage form of claim 17 , wherein the dosage form is suitable for oral administration.

19. A dosage form comprising a composition of claim 1 , wherein the dosage form is suitable for parenteral administration.

20. The dosage form of claim 19 , wherein the parenteral administration is selected from injection or intravenous infusion.

21. A method of administering a composition of claim 1 to a patient in need thereof, comprising parenterally administering the composition to the patient.

22. A method of administering a composition of claim 1 to a patient in need thereof, comprising orally administering the composition to the patient.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2014
From: STAPLES, MARK; ROLKE, JAMES
To: GLYCOGENESYS, INC.
Reel/Frame 032391/0179 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2014
From: GLYCOGENESYS, INC.
To: MARLBOROUGH RESEARCH AND DEVELOPMENT INC.
Reel/Frame 032391/0201 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2014
From: PROSPECT PHARMACEUTICALS, INC.
To: TANG CAPITAL PARTNERS LP
Reel/Frame 032391/0243 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2014
From: TANG CAPTIAL PARTNERS, LP
To: SOLANA THERAPEUTICS, INC.
Reel/Frame 032391/0262 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2014
From: SOLANA THERAPEUTICS, INC.
To: LA JOLLA PHARMACEUTICAL COMPANY
Reel/Frame 032391/0280 →
CHANGE OF NAME Recorded Mar 10, 2014
From: PROSPECT PHARMACEUTICALS, INC.
To: PROSPECT THERAPEUTICS, INC.
Reel/Frame 032422/0192 →
CHANGE OF NAME Recorded Mar 10, 2014
From: MARLBOROUGH RESEARCH AND DEVELOPMENT INC.
To: PROSPECT PHARMACEUTICALS, INC.
Reel/Frame 032510/0072 →